
The NeuroMuscular Omnicentre (NeMO) is based at the Niguarda Ca’ Granda Hospital in Milan and is part of a network that consists of four clinical facilities distributed throughout Italy. We are a highly specialized center and devoted to take care of people affected with neuromuscular diseases, including ALS. We follow over 1000 neuromuscular patients each year. Using the expertise of our multidisciplinary team of specialists, we aim to cover the overall needs of ALS patients. We do this by offering comprehensive services in the areas of diagnosis, treatment, rehabilitation, nutrition and pulmonary care.
Contact
LocationPiazza dell'Ospedale Maggiore, 3, 20162 Milan, Metropolitan City of Milan, Italy
Our Specialists
Current trials
Recruiting
Phase iii
PHOENIX trial
Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Recruiting
Phase iii
ADORE Trial
Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Recruiting
Phase iii
COURAGE-ALS Trial
Industry trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
Active
Phase ii
APL2-ALS-206 Trial
Industry trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
Active
Phase ii
RT001 in Amyotrophic Lateral Sclerosis
Industry trial
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
Recruiting
Phase iii
TUDCA-ALS
Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.